{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T02:30:21Z","timestamp":1787797821204,"version":"build-2784847793"},"reference-count":12,"publisher":"MDPI AG","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Am Podiatr Med Assoc"],"published-print":{"date-parts":[[2012,9]]},"abstract":"<jats:p>Laser systems are a new treatment area for onychomycosis. As of January 2012, the US Food and Drug Administration (FDA) has approved four laser systems for the \u201ctemporary increase of clear nail in onychomycosis.\u201d The FDA has approved these devices on the basis of \u201csubstantial equivalence\u201d to predicate devices with similar technical specifications and applications. Laser therapy appears to be a promising alternative to traditional pharmacotherapy, but these systems have been tested in only limited clinical trials; therefore, it is not possible to compare their efficacy to the oral and topical drugs currently used in the treatment of onychomycosis. (J Am Podiatr Med Assoc 102 (5): 428-430, 2012)<\/jats:p>","DOI":"10.7547\/1020428","type":"journal-article","created":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T09:47:20Z","timestamp":1396345640000},"page":"428-430","source":"Crossref","is-referenced-by-count":22,"title":["Newly Approved Laser Systems for Onychomycosis"],"prefix":"10.3390","volume":"102","author":[{"given":"Aditya K.","family":"Gupta","sequence":"first","affiliation":[{"name":"Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Canada."},{"name":"Mediprobe Research Inc, London, Ontario, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Simpson","sequence":"additional","affiliation":[{"name":"Mediprobe Research Inc, London, Ontario, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","reference":[{"key":"b1-1020428","series-title":"Cutis","first-page":"10","article-title":"Onychomycosis: review of recurrence rates, poor prognostic factors, and strategies to prevent disease recurrence.","volume":"74","author":"Gupta, AK","year":"2004","unstructured":"Gupta, AK and LELynch. :Onychomycosis: review of recurrence rates, poor prognostic factors, and strategies to prevent disease recurrence. .Cutis74::10. ,2004. .15287395"},{"issue":"Suppl 65","key":"b2-1020428","series-title":"Br J Dermatol","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1046\/j.1365-2133.149.s65.5.x","article-title":"Onychomycosis in clinical practice: factors contributing to recurrence.","volume":"149","author":"Scher, RK","year":"2003","unstructured":"Scher, RK and RBaran. :Onychomycosis in clinical practice: factors contributing to recurrence. .Br J Dermatol149( Suppl 65:):5. ,2003. .1451096910.1046\/j.1365-2133.149.s65.5.x"},{"key":"b3-1020428","series-title":"Summary K093547: PinPointe FootLaser, PinPointe USA, Inc","article-title":"510(k) Database.","unstructured":"US Food and Drug Administration\n           :510(k) Database. .Summary K093547: PinPointe FootLaser, PinPointe USA, Inc .Available at: http:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf9\/K093547.pdf. .Accessed October 3, 2011."},{"key":"b4-1020428","series-title":"Australian Register of Therapeutic Goods: Public Summary 163176","unstructured":"Australian Register of Therapeutic Goods: Public Summary 163176 .Available at: https:\/\/www.ebs.tga.gov.au\/servlet\/xmlmillr6?dbid=ebs\/PublicHTML\/pdfStore.nsf&docid=163176&agid=(PrintDetailsPublic)&actionid=1. .Accessed November 1, 2011."},{"key":"b5-1020428","series-title":"Proc of SPIE","first-page":"1","article-title":"Laser treatment for toenail fungus.","volume":"71610","author":"Harris, DM","year":"2009","unstructured":"Harris, DM, BAMcDowell, and JStristower. :Laser treatment for toenail fungus. .Proc of SPIE71610::1. ,2009. ."},{"key":"b6-1020428","series-title":"Summary K103626: Cutera GenesisPlus Laser System, Cutera, Inc","article-title":"510(k) Database.","unstructured":"US Food and Drug Administration\n           :510(k) Database. .Summary K103626: Cutera GenesisPlus Laser System, Cutera, Inc .Available at: http:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf10\/K103626.pdf. .Accessed October 3, 2011."},{"key":"b7-1020428","series-title":"3 month clinical results using sub-millisecond 1064nm Nd:YAG laser for the treatment of onychomycosis","author":"Weiss, D","unstructured":"Weiss, D\n          . :3 month clinical results using sub-millisecond 1064nm Nd:YAG laser for the treatment of onychomycosis .Available at: http:\/\/conejofeet.com\/wp-content\/uploads\/2011\/06\/David-Weiss-DPM-report.pdf. .Accessed November 2011."},{"key":"b8-1020428","series-title":"Summary K103338: CoolTouch VARIA, New Star Lasers, Inc","article-title":"510(k) Database.","unstructured":"US Food and Drug Administration\n           :510(k) Database. .Summary K103338: CoolTouch VARIA, New Star Lasers, Inc .Available at: http:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf6\/K060966.pdf. .Accessed November 1, 2011."},{"key":"b9-1020428","series-title":"Summary K110370. Q-Clear, Light Age, Inc","article-title":"510(k) Database.","unstructured":"US Food and Drug Administration\n           :510(k) Database. .Summary K110370. Q-Clear, Light Age, Inc .Available: http:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf11\/K110370.pdf. .Accessed November 2011."},{"key":"b10-1020428","series-title":"Lamisil Product Label, Novartis","unstructured":"Drugs@FDA Database\n           :Lamisil Product Label, Novartis .Available at: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/020539s018lbl.pdf. .Accessed October 2011."},{"key":"b11-1020428","series-title":"Sporanox Product Label, Janssen Pharms","unstructured":"Drugs@FDA Database\n           :Sporanox Product Label, Janssen Pharms .Available at: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/020083s046lbl.pdf. .Accessed November 1, 2011."},{"key":"b12-1020428","series-title":"Penlac Product Label, Sanofi Aventis","unstructured":"Drugs@FDA Database\n           :Penlac Product Label, Sanofi Aventis .Available at: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2004\/21022s004lbl.pdf. .Accessed November 1, 2011."}],"container-title":["Journal of the American Podiatric Medical Association"],"original-title":[],"link":[{"URL":"https:\/\/japmaonline.org\/view\/journals\/apms\/102\/5\/1020428.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/meridian.allenpress.com\/japma\/article-pdf\/102\/5\/428\/1405156\/1020428.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/japmaonline.org\/downloadpdf\/journals\/apms\/102\/5\/1020428.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/japmaonline.org\/downloadpdf\/journals\/apms\/102\/5\/1020428.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T10:12:20Z","timestamp":1783505540000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1930-8264\/102\/5\/428"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":12,"journal-issue":{"issue":"5"},"URL":"https:\/\/doi.org\/10.7547\/1020428","relation":{},"ISSN":["8750-7315","1930-8264"],"issn-type":[{"value":"8750-7315","type":"print"},{"value":"1930-8264","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}